Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?

Bone Marrow Transplantation volume 52, pages 1225–1232 (2017)Cite this article

Subjects

Abstract

The discovery of T regulatory cells has been one of the most important advances in basic immunology and has opened the door to the development of innovative therapeutic strategies for improving the outcome of solid organ and hematopoietic stem cell transplantation. Basic immunology is rapidly elucidating the complex biology of these cells even though the difficulties in purifying or even expanding them in vitro represent a major limitation to the development of clinical studies. The clinical benefit potentially associated with this therapeutic approach remains to be demonstrated. Meanwhile, several drugs used for the treatment of hematologic malignancies or for other purposes have been shown to upregulate the number and function of Tregs in vivo. In the near future, both ex vivo or in vivo expanded T cells are likely to enter the therapeutic armamentarium of clinical transplantation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M . Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151–1164.

    CAS  PubMed  Google Scholar 

  2. Shevach EM . Immunology. Regulating suppression. Science 2008; 322: 202–203.

    Article  CAS  PubMed  Google Scholar 

  3. Shevach EM . Special regulatory T cell review: how I became a T suppressor/regulatory cell maven. Immunology 2008; 123: 3–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bluestone JA, Abbas AK . Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3: 253–257.

    Article  CAS  PubMed  Google Scholar 

  5. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 2013; 14: 307–308.

    Article  CAS  PubMed  Google Scholar 

  6. Fontenot JD, Gavin MA, Rudensky AY . Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330–336.

    Article  CAS  PubMed  Google Scholar 

  7. Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057–1061.

    Article  CAS  PubMed  Google Scholar 

  8. Khattri R, Cox T, Yasayko SA, Ramsdell F . An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4: 337–342.

    Article  CAS  PubMed  Google Scholar 

  9. Sakaguchi S, Miyara M, Costantino CM, Hafler DA . FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490–500.

    Article  CAS  PubMed  Google Scholar 

  10. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA . CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245–1253.

    Article  CAS  PubMed  Google Scholar 

  11. Hsieh C-S, Lee H-M, Lio C-WJ . Selection of regulatory T cells in the thymus. Nat Rev Immunol 2012; 12: 157–167.

    Article  CAS  PubMed  Google Scholar 

  12. Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE, Lerman MA et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001; 2: 301–306.

    Article  CAS  PubMed  Google Scholar 

  13. Chen W, Jin W, Hardegen N, Lei K-j Li L, Marinos N et al. Conversion of peripheral CD4+CD25− naive T Cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875–1886.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Liu C, Workman CJ, Vignali DAA . Targeting regulatory T cells in tumors. FEBS J 2016; 283: 2731–2748.

    Article  CAS  PubMed  Google Scholar 

  15. Alice Long S, Buckner JH . CD4(+)FOXP3(+) Treg in human autoimmunity: more than a numbers game. J Immunol 2011; 187: 2061–2066.

    Article  PubMed  Google Scholar 

  16. Nguyen VH, Shashidhar S, Chang DS, Ho L, Kambham N, Bachmann M et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 2008; 111: 945–953.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Nguyen VH, Zeiser R, Dasilva DL, Chang DS, Beilhack A, Contag CH et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 2007; 109: 2649–2656.

    Article  CAS  PubMed  Google Scholar 

  18. Taylor PA, Lees CJ, Blazar BR . The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493–3499.

    Article  CAS  PubMed  Google Scholar 

  19. Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003; 112: 1688–1696.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bolton HA, Zhu E, Terry AM, Guy TV, Koh WP, Tan SY et al. Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease. J Clin Invest 2015; 125: 3627–3641.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144–1150.

    Article  CAS  PubMed  Google Scholar 

  22. Ruggeri L, Di Ianni M, Urbani E, Mancusi A, Falzetti F, Carotti A et al. Tregs suppress GvHD at the periphery and unleash the Gvl effect in the bone marrow. Blood 2014; 124: 842–842.

    Article  Google Scholar 

  23. Sandy AR, Chung J, Toubai T, Shan GT, Tran IT, Friedman A et al. T cell-specific notch inhibition blocks graft-versus-host disease by inducing a hyporesponsive program in alloreactive CD4+ and CD8+ T cells. J Immunol 2013; 190: 5818–5828.

    Article  CAS  PubMed  Google Scholar 

  24. Tran IT, Sandy AR, Carulli AJ, Ebens C, Chung J, Shan GT et al. Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest 2013; 123: 1590–1604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Zhang Y, Sandy AR, Wang J, Radojcic V, Shan GT, Tran IT et al. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. Blood 2011; 117: 299–308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Del Papa B, Pierini A, Sportoletti P, Baldoni S, Cecchini D, Rosati E et al. The NOTCH1/CD39 axis: a Treg trip-switch for GvHD. Leukemia 2016; 30: 1931–1934.

    Article  CAS  PubMed  Google Scholar 

  27. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921–3928.

    Article  CAS  PubMed  Google Scholar 

  28. Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 2014; 124: 638–644.

    Article  CAS  PubMed  Google Scholar 

  29. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108: 1291–1297.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Pabst C, Schirutschke H, Ehninger G, Bornhauser M, Platzbecker U . The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin Cancer Res 2007; 13: 2916–2922.

    Article  CAS  PubMed  Google Scholar 

  31. Wolf D, Wolf AM, Fong D, Rumpold H, Strasak A, Clausen J et al. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2007; 83: 1107–1113.

    Article  PubMed  Google Scholar 

  32. Pastore D, Delia M, Mestice A, Carluccio P, Perrone T, Gaudio F et al. CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 887–893.

    Article  CAS  PubMed  Google Scholar 

  33. Delia M, Pastore D, Mestice A, Carluccio P, Perrone T, Gaudio F et al. Outcome of allogeneic peripheral blood stem cell transplantation by donor graft CD3+/Tregs ratio: a single-center experience. Biol Blood Marrow Transplant 2013; 19: 495–499.

    Article  PubMed  Google Scholar 

  34. Noel G, Bruniquel D, Birebent B, DeGuibert S, Grosset JM, Bernard M et al. Patients suffering from acute graft-versus-host disease after bone-marrow transplantation have functional CD4+CD25hiFoxp3+ regulatory T cells. Clin Immunol 2008; 129: 241–248.

    Article  CAS  PubMed  Google Scholar 

  35. Rosenzwajg M, Dhedin N, Maury S, Bensimon G, Landau DA, Norol F et al. Regulatory T cell content in the bone marrow graft does not predict the occurrence of acute GVHD. Biol Blood Marrow Transplant 2011; 17: 265–269.

    Article  PubMed  Google Scholar 

  36. Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D et al. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood 2004; 103: 1140–1146.

    Article  CAS  PubMed  Google Scholar 

  37. Danby RD, Zhang W, Medd P, Littlewood TJ, Peniket A, Rocha V et al. High proportions of regulatory T cells in PBSC grafts predict improved survival after allogeneic haematopoietic SCT. Bone Marrow Transplant 2016; 51: 110–118.

    Article  CAS  PubMed  Google Scholar 

  38. Clark FJ, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004; 103: 2410–2416.

    Article  CAS  PubMed  Google Scholar 

  39. Ukena SN, Grosse J, Mischak-Weissinger E, Buchholz S, Stadler M, Ganser A et al. Acute but not chronic graft-versus-host disease is associated with a reduction of circulating CD4(+)CD25 (high)CD127 (low/-) regulatory T cells. Ann Hematol 2011; 90: 213–218.

    Article  CAS  PubMed  Google Scholar 

  40. Zorn E, Mohseni M, Kim H, Porcheray F, Lynch A, Bellucci R et al. Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 382–388.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Fujioka T, Tamaki H, Ikegame K, Yoshihara S, Taniguchi K, Kaida K et al. Frequency of CD4(+)FOXP3(+) regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD. Bone Marrow Transplant 2013; 48: 859–864.

    Article  CAS  PubMed  Google Scholar 

  42. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061–1070.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood 2016; 127: 1044–1051.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M . Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 2004; 104: 895–903.

    Article  CAS  PubMed  Google Scholar 

  45. Hoffmann P, Boeld TJ, Eder R, Albrecht J, Doser K, Piseshka B et al. Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant 2006; 12: 267–274.

    Article  CAS  PubMed  Google Scholar 

  46. Peters JH, Preijers FW, Woestenenk R, Hilbrands LB, Koenen HJ, Joosten I . Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation. PLoS ONE 2008; 3: e3161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Samuel ER, Beloki L, Newton K, Mackinnon S, Lowdell MW . Isolation of highly suppressive CD25+FoxP3+ T regulatory cells from G-CSF-mobilized donors with retention of cytotoxic anti-viral CTLs: application for multi-functional immunotherapy post stem cell transplantation. PLoS ONE 2014; 9: e85911.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Patel P, Mahmud D, Park Y, Yoshinaga K, Mahmud N, Rondelli D . Clinical grade isolation of regulatory T cells from G-CSF mobilized peripheral blood improves with initial depletion of monocytes. Am J Blood Res 2015; 5: 79–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Edinger M, Hoffmann P . Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol 2011; 23: 679–684.

    Article  CAS  PubMed  Google Scholar 

  50. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.

    Article  PubMed  Google Scholar 

  51. Trzonkowski P, Bieniaszewska M, Juscinska J, Dobyszuk A, Krzystyniak A, Marek N et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol 2009; 133: 22–26.

    Article  CAS  PubMed  Google Scholar 

  52. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A . Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007; 178: 320–329.

    Article  CAS  PubMed  Google Scholar 

  53. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365: 2055–2066.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Matsuoka K-i, Koreth J, Kim HT, Bascug OG, McDonough S, Kawano Y et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013; 5: 179ra143.

    Article  CAS  Google Scholar 

  55. Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft vs. host disease. Blood 2016; 128: 130–137.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res 2014; 20: 2215–2225.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Fehniger TA, Bluman EM, Porter MM, Mrózek E, Cooper MA, VanDeusen JB et al. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest 2000; 106: 117–124.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Soiffer R, Murray C, Gonin R, Ritz J . Effect of low-dose interleukin-2 on disease relapse after T-cell- depleted allogeneic bone marrow transplantation. Blood 1994; 84: 964–971.

    CAS  PubMed  Google Scholar 

  59. Sharma R, Fu SM, Ju S-T . IL-2: A two-faced master regulator of autoimmunity. J Autoimmun 2011; 36: 91–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Kong YY, Eto M, Omoto K, Umesue M, Hashimoto A, Nomoto K . Regulatory T cells in maintenance and reversal of peripheral tolerance in vivo. J Immunol 1996; 157: 5284–5289.

    CAS  PubMed  Google Scholar 

  61. Tomita Y, Mayumi H, Eto M, Nomoto K . Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance? J Immunol 1990; 144: 463–473.

    CAS  PubMed  Google Scholar 

  62. Ganguly S, Ross DB, Panoskaltsis-Mortari A, Kanakry CG, Blazar BR, Levy RB et al. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood 2014; 124: 2131–2141.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Kanakry CG, Ganguly S, Zahurak M, Bolanos-Meade J, Thoburn C, Perkins B et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 2013; 5: 211ra157.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Kanakry CG, Tsai HL, Bolanos-Meade J, Smith BD, Gojo I, Kanakry JA et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 2014; 124: 3817–3827.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Battaglia M, Stabilini A, Roncarolo MG . Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105: 4743–4748.

    Article  CAS  PubMed  Google Scholar 

  66. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008; 111: 453–462.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MT et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 2015; 29: 396–405.

    Article  CAS  PubMed  Google Scholar 

  68. Cieri N, Greco R, Crucitti L, Morelli M, Giglio F, Levati G et al. Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells. Biol Blood Marrow Transplant 2015; 21: 1506–1514.

    Article  CAS  PubMed  Google Scholar 

  69. Servais S, Menten-Dedoyart C, Beguin Y, Seidel L, Gothot A, Daulne C et al. Impact of pre-transplant anti-T cell globulin (ATG) on immune recovery after myeloablative allogeneic peripheral blood stem cell transplantation. PLoS ONE 2015; 10: e0130026.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010; 116: 129–139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012; 119: 3361–3369.

    Article  CAS  PubMed  Google Scholar 

  72. Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, Caballero-Velazquez T, Blanco B, Herrero-Sanchez C et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010; 115: 107–121.

    Article  CAS  PubMed  Google Scholar 

  73. Schroeder T, Frobel J, Cadeddu RP, Czibere A, Dienst A, Platzbecker U et al. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia 2013; 27: 1910–1913.

    Article  CAS  PubMed  Google Scholar 

  74. de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol 2011; 31: 2066–2078.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004; 101: 3921–3926.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM et al. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 2014; 15: 87–95.

    Article  CAS  PubMed  Google Scholar 

  77. Choi SW, Gatza E, Hou G, Sun Y, Whitfield J, Song Y et al. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. Blood 2015; 125: 815–819.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Massa M, Rosti V, Campanelli R, Fois G, Barosi G . Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia 2014; 28: 449–451.

    Article  CAS  PubMed  Google Scholar 

  79. Massa M, Campanelli R, Fois G, Villani L, Bonetti E, Catarsi P et al. Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis. Blood 2016; 128: 1660–1662.

    Article  CAS  PubMed  Google Scholar 

  80. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117–1127.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Parampalli Yajnanarayana S, Stubig T, Cornez I, Alchalby H, Schonberg K, Rudolph J et al. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol 2015; 169: 824–833.

    Article  CAS  PubMed  Google Scholar 

  82. Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 2014; 123: 3832–3842.

    Article  CAS  PubMed  Google Scholar 

  83. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015; 29: 2062–2068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

    F Lussana & A Rambaldi

  2. Department of Life, Hematology Section, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy

    M Di Ianni

  3. Department of Oncology-Hematology Università degli Studi di Milano, Milan, Italy

    A Rambaldi

Authors
  1. F Lussana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Di Ianni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Rambaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Rambaldi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lussana, F., Di Ianni, M. & Rambaldi, A. Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?. Bone Marrow Transplant 52, 1225–1232 (2017). https://doi.org/10.1038/bmt.2017.30

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.30

This article is cited by

Search

Advanced search

Quick links